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The paradox of cancer genes in non-
malignant conditions: implications for
precision medicine
Jacob J. Adashek1†, Shumei Kato2†, Scott M. Lippman2† and Razelle Kurzrock2*†
Abstract
Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown
remarkable efficacy in cancers that have the cognate molecular signatures. Intriguingly, rapidly emerging data
indicate that altered genes representing oncogenic drivers can also be found in sporadic non-malignant conditions,
some of which have negligible and/or low potential for transformation to cancer. For instance, activating KRAS
mutations are discerned in endometriosis and in brain arteriovenous malformations, inactivating TP53 tumor
suppressor mutations in rheumatoid arthritis synovium, and AKT, MAPK, and AMPK pathway gene alterations in the
brains of Alzheimer’s disease patients. Furthermore, these types of alterations may also characterize hereditary
conditions that result in diverse disabilities and that are associated with a range of lifetime susceptibility to the
development of cancer, varying from near universal to no elevated risk. Very recently, the repurposing of targeted
cancer drugs for non-malignant conditions that are associated with these genomic alterations has yielded
therapeutic successes. For instance, the phenotypic manifestations of CLOVES syndrome, which is characterized by
tissue overgrowth and complex vascular anomalies that result from the activation of PIK3CA mutations, can be
ameliorated by the PIK3CA inhibitor alpelisib, which was developed and approved for breast cancer. In this review,
we discuss the profound implications of finding molecular alterations in non-malignant conditions that are
indistinguishable from those driving cancers, with respect to our understanding of the genomic basis of medicine,
the potential confounding effects in early cancer detection that relies on sensitive blood tests for oncogenic
mutations, and the possibility of reverse repurposing drugs that are used in oncology in order to ameliorate non-
malignant illnesses and/or to prevent the emergence of cancer.
Background
In recent years, the rate of development of small molecule
and antibody drugs that effectively target oncogenic drivers
has increased rapidly [1, 2]. The natural question that
emerges is whether or not targeting these genomic alter-
ations in non-malignant illness could also have salutary ef-
fects, as there are (i) benign conditions (including but not
limited to seborrheic keratosis, endometriosis, arterioven-
ous malformations in the brain, and Alzheimer’s disease)
that arise sporadically and that harbor somatic mutations
that are believed to be drivers in cancer (Table 1), and (ii)
germline and hereditary phenotypes and somatic mosaic
phenotypes that are associated with such mutations (e.g.,
achondroplasia, neurofibromatosis, CLOVES syndrome,
and Proteus syndrome) (Table 2). The benign disorders
that harbor putative “oncogenic drivers” have a variable
propensity for malignant transformation and, in the case of
hereditary conditions that are caused by such mutations,
patients have differing vulnerabilities for the development
of malignancy, ranging from minimal or no increased risk
to a very high lifetime susceptibility to cancer.
Interestingly, there is also growing evidence that the
canonical theory of renegade clonal expansion in car-
cinogenesis [116] may not be the only manner in which
malignant development proceeds. The theory of clonal
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Table 1 Examples of sporadic benign conditions, many with negligible potential for malignant transformation, associated with
somatic alterations in driver cancer genes
Gene Type of
alteration
Benign or
premalignant
condition
Frequency of
alteration in
benign
condition (%)
Examples of drug(s) that can potentially
target the alteration
Examples of
malignancies
associated with this
gene alteration
Mechanism
BRAF V600E, D594V,
V599E
Melanocytic
nevi
70–88% [3–
12]
BRAF and/or MEK inhibitors such as
dabrafenib and trametanib [13, 14]
Melanoma RAS-RAF-MEK-
ERK pathway
upregulation
[15]
NRAS Q61K Giant
congenital
melanocytic
nevi
6–14% [10,
11]
MEK inhibitors [12] such as trametinib [16] Melanoma RAS-RAF-MEK-
ERK pathway
upregulation
[15]
Q61K and
Q61R
Melanocytic
nevi
70–95%
[17, 18]
MEK inhibitors such as trametinib [16] Melanoma RAS-RAF-MEK-
ERK pathway
upregulation
[15]
FGFR3 R248C, S249C,
G372C, S373C,
A393E, K652E,
K652M
Seborrheic
keratosis
∼ 18–85%
[19–22]
FGFR inhibitors such as erdafitinib [23] Urothelial carcinoma Activation of
the FGF/FGFR
machinery [24]
R248C, G372C,
G382R
Epidermal nevi 33% [25] FGFR inhibitors such as erdafitinib [23] Urothelial carcinoma Activation of
the FGF/FGFR
machinery [24]
PIK3CA E542K, E545K,
H1047R
Seborrheic
keratosis
∼ 16% [20] PIK3CA inhibitors such as alpelisib [26] Breast cancer PI3K-AKT-mTOR
pathway
activation
M1043V Endometriosis ~ 4% [27] PIK3CA inhibitors such as alpelisib [26] Breast cancer PI3K-AKT-mTOR
pathway
activation
H1047L,
H1047R
Normal
esophagus
mucosa
Not listed
[28]
PIK3CA inhibitors such as alpelisib [26] Breast cancer PI3K-AKT-mTOR
pathway
activation
ALK TPM3-ALK,
TPM4-ALK
Inflammatory
myofibroblastic
tumor
∼ 50% [29] ALK inhibitors [30] such as alectinib [31] Non-small cell lung
cancer
ALK pathway
activation [32]
NOTCH1 Loci not
specified
Aging
esophagus
12–80% [33] No specific inhibitors approved Colon cancer Wnt-beta-
catenin pathway
activation [34]
KRAS G12V or G12D Arteriovenous
malformations
in brain
∼ 63% [35,
36]
MEK inhibitors such as trametinib [16] Colorectal and
pancreatic cancer
RAS-RAF-MEK-
ERK pathway
upregulation
[15]
G12C, G12V,
G12A, G12D,
G12R
Endometriosis ~ 21% [27] MEK inhibitors such as trametinib [16] Colorectal and
pancreatic cancer
RAS-RAF-MEK-
ERK pathway
upregulation
[15]
Q61R Normal testis Not listed
[28]
MEK inhibitors such as trametinib [16] Colorectal and
pancreatic cancer
RAS-RAF-MEK-
ERK pathway
upregulation
[15]
TP53 R177S, Q192L,
R196*, K139R,
H193Y, E224fs,
N239S
Rheumatoid
arthritis
synovium
17–46% [37,
38]
Bevacizumab may target angiogenesis
upregulation that results from TP53
mutations [39]
Serous ovarian cancer
(TP53 mutations are
common across
cancers)
TP53 is a tumor
suppressor gene
[40]
Loci not
specified
Aging
esophagus
2–37% [33] Bevacizumab may target angiogenesis
upregulation that results from TP53
mutations [39]
Serous ovarian cancer
(TP53 mutations are
common across
cancers)
TP53 is a tumor
suppressor gene
[40]
CTNNB1 T41A and
S45P
Desmoid
tumor
88% [41] COX-2 inhibitors [42] such as celecoxib [43],
as well as sorafenib (which can suppress
Adrenocortical
cancers
Wnt-beta-
catenin pathway
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expansion posits that clones of cells harboring oncogenic
drivers will be selected during the development of malig-
nancy because these driver(s) confer a growth advantage.
Hence, the percentage of cells with the oncogenic
driver(s) will be smaller in premalignant lesions than in
lesions that are malignant. However, the opposite is
sometimes found (Fig. 1). For instance, BRAF V600E
driver mutations are discerned at twice the frequency in
benign nevi, which do not transform to melanoma, than
in melanoma itself [3, 4, 117]. This paradoxical
phenomenon has also been reported in the continuum
from benign to malignant in other diseases (Fig. 1).
There are several important consequences of “onco-
genic drivers” in benign conditions. First, there are the
implications for early detection of cancer based on sensi-
tive blood tests that assess circulating cell-free DNA
(cfDNA) [130–132]. If mutations identical to those
found in cancer also occur in conditions with no malig-
nant predisposition, their presence may confound the
early diagnosis of cancer premise that is the basis of
these blood-based screening tests, such as the multi-
cancer detection blood test developed by GRAIL that
has been granted breakthrough status by the US Food
and Drug Administration [133].
Furthermore, as mutations that are indistinguishable
from those in cancer exist in benign conditions, and as
drugs are available that effectively neutralize the impact
of these mutations in cancer, it is plausible that these
drugs could be repurposed for illnesses other than can-
cer. Indeed, several such examples have been established
in preclinical models and in patients. For instance, it has
recently been demonstrated that increased expression of
PARP1, a well-known anti-apoptotic cancer target, plays
a role in neuronal cell death in Parkinson’s disease. Con-
sequently, it has been suggested that PARP inhibitors,
which have successfully been used to treat BRCA-mu-
tated cancers [134–137], merit examination as candidate
drugs in Parkinson’s disease [138]. In BRCA-mutated tu-
mors, repair of double-stranded DNA breaks is deficient.
PARP1 is a protein that is important for repairing
single-strand breaks; and the suppression of PARP
catalytic activity by PARP inhibitors further compro-
mises DNA repair, resulting in tumor cell lethality. In
Parkinson’s disease, PARP is elevated and causes alpha-
synuclein spread, triggering cell death and Parkinson’s
symptoms; theoretically, PARP inhibitors could reverse
this process.
Another example in which a drug developed for cancer
can be used in a non-cancer condition is provided by
CLOVES syndrome, which is caused by mutations in
PIK3CA. Patients with CLOVES syndrome, which mani-
fests as congenital lipomatous overgrowth, vascular mal-
formations, epidermal nevi, and scoliosis/skeletal and
spinal anomalies, also have a propensity to Wilms tu-
mors [112]. CLOVES syndrome can be treated with the
PIK3CA inhibitor alpelisib, which was developed for
PIK3CA-mutant breast cancer [113].
In this review, we provide an overview of and update
on the rapidly expanding knowledge regarding the con-
undrum of oncogenic drivers in benign disorders, and
we discuss the profound implications of these findings
for the treatment of both benign and malignant condi-
tions [139]. First, the ubiquitous finding of oncogenic
drivers in non-malignant conditions may prove problem-
atic for the development of sensitive blood tests for early
detection of cancer. Second, non-malignant conditions
that are caused by actionable oncogenic drivers could
potentially be treated with repurposed drugs that have
been successfully developed to target and manage can-
cers harboring those drivers. Examples of such effective
repurposing already exist, suggesting that the molecular
alterations found in benign disease are indeed drivers of
benign disease (as they are in cancer) and not “unin-
volved bystanders.” Such strategies are especially import-
ant because some of the benign conditions in which
these mutations have been found are rare or ultra-rare
and present a huge unmet therapeutic need. Import-
antly, some non-malignant conditions are associated
Table 1 Examples of sporadic benign conditions, many with negligible potential for malignant transformation, associated with
somatic alterations in driver cancer genes (Continued)
Gene Type of
alteration
Benign or
premalignant
condition
Frequency of
alteration in
benign
condition (%)
Examples of drug(s) that can potentially
target the alteration
Examples of
malignancies
associated with this
gene alteration
Mechanism
CTNNB1-mediated activation of the WNT
pathway) [13, 14, 44]
activation [45]
FGFR2 Y376C, P286S Keratinocytic
epidermal
nevus
5–10% [46] FGFR inhibitors such as erdafitinib [23] Urothelial carcinoma FGF/FGFR
machinery [24]
AKT, MAPK,
and AMPK
pathway
genes
– Alzheimer’s
disease
~ 27% [47] mTOR inhibitors or MEK inhibitors Multiple tumor types Increases tau
phosphorylation
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Table 2 Examples of hereditary germline syndromes and of somatic mosaicism associated with examples of alterations in cancer-
driver genes, their relationship with cancer in affected patients, and targeted drugs that might be useful
Gene Alteration Syndrome Descriptions Increased incidence of
cancer (if yes, most
common cancers)
Treatment potentially/
theoretically targeting the
alteration
APC Most
common
nonsense
changes are
C>T
mutations
[48]
Familial adenomatous
polyposis [49]
Multiple non-cancerous (benign)
growths (polyps) in the colon
with strong predisposition to
cancer
Yes (colorectal [49, 50]) Sorafenib and WNT inhibitors
[13, 44]
ARAF S214P [51] Central conducting
lymphatic anomaly
[52]
Not listed None found mTOR inhibitors such as
sirolimus [53] or MEK inhibitors
such as trametinib [51]
BRAF Q257R,
S467A,
G596V,
V600G
Cardiofaciocutaneous
syndrome [54]
Cardiac abnormalities, distinctive
craniofacial appearance, and
cutaneous abnormalities
Yes (juvenile
myelomonocytic leukemia,
brain tumors, acute
lymphoblastic leukemia,
rhabdomyosarcoma, and
neuroblastoma [55])
BRAF inhibitors [9] and/or MEK
inhibitors such as dabrafenib
[5] and cobimetinib [7]
G469E,
F595L,
L597V
Noonan syndrome
[56, 57]
Unusual facial features, short
stature, heart defects, bleeding
problems, and skeletal
malformations
Yes (juvenile
myelomonocytic leukemia,
brain tumor, acute
lymphoblastic leukemia,
rhabdomyosarcoma, and
neuroblastoma [55])
–
ERBB4 R927Q,
R1275W
Amyotrophic lateral
sclerosis subtype 19
[58]
Degeneration of motor neurons
and anterior horns of spinal cord
None found Pan-ERBB inhibitors such as
neratinib [59] will not be
effective because the
mutations have an inactivating
effect
FGFR1 L165S,
L191S
Hartsfield syndrome
[60]
Holoprosencephaly, ectrodactyly,
and cleft lip/palate
None found These FGFR1 mutations may
cause loss of function, so FGFR
inhibitors such as erdafitinib
[23] will not be effective
Multiple
loss of
function
mutations
Kallman syndrome
[61]
Hypogonadotropic
hypogonadism and impaired
sense of smell
None found –
P252R Pfeiffer syndrome [62] Premature fusion of certain skull
bones
None found Gain-of-function alterations
and hence may be targeted by
FGFR inhibitors such as
erdafitinib [23]
FGFR2 S252W or
P253R
Apert syndrome [63] Premature fusion of certain skull
bones (craniosynostosis*) and
syndactyly
Hepatoblastoma [64]* Mutations are gain of function
and hence may be targeted by
FGFR inhibitors such as
erdafitinib [23]
Y375C or
S372C
Beare-Stevenson cutis
gyrata syndrome [65]
Premature fusion of certain skull
bones (craniosynostosis*)
Hepatoblastoma [64]* –
S351C Pfeiffer syndrome [62] Premature fusion of certain skull
bones (craniosynostosis*)
Hepatoblastoma [64]* –
FGFR3 G380R;
R248C,
G372C,
G382R
Achondroplasia [66] Short-limbed dwarfism None found Mutations are gain of function
and hence may be targeted by
FGFR inhibitors such as
erdafitinib [23]
N540K Hypochondroplasia
[67]
Short-limbed dwarfism that is
milder than achondroplasia
None found –
D513N Lacrimo-auriculo-
dento-digital
syndrome [68]
Abnormal tear production,
malformed ears with hearing
loss, decreased saliva production,
small teeth, and hand
deformities
None found –
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Table 2 Examples of hereditary germline syndromes and of somatic mosaicism associated with examples of alterations in cancer-
driver genes, their relationship with cancer in affected patients, and targeted drugs that might be useful (Continued)
Gene Alteration Syndrome Descriptions Increased incidence of
cancer (if yes, most
common cancers)
Treatment potentially/
theoretically targeting the
alteration
P250R Muenke syndrome
[69]
Craniosynostosis*, hearing loss,
subtle hand and foot abnormalities,
and developmental delay
Hepatoblastoma [64]* –
R248C,
K650E,
S249C,
Y373C
Thanatophoric
dysplasia [70]
Extremely short limbs and folds of
extra (redundant) skin on the arms
and legs
None found FGFR3 inhibitor in mice [71]
GNAS R201C,
R201H,
Q227L
McCune-Albright
syndrome [72]
Abnormal scar-like (fibrous) tissue in
their bones, a condition called
polyostotic fibrous dysplasia
Yes (breast, thyroid,
testicular [73])
MEK inhibitors [74] such as
trametinib [75]
HRAS G12S,
G12C
Costello syndrome Delayed development/intellectual
disability, loose folds of skin, unusually
flexible joints, and distinctive facial
features including a large mouth,
heart problems
Yes (juvenile
myelomonocytic leukemia,
brain tumor, acute
lymphoblastic leukemia,
rhabdomyosarcoma, and
neuroblastoma [55])
MEK inhibitors [76] such as
trametinib [75]
IDH2 R140Q D-2-hydroxyglutaric
aciduria [77]
Delayed development, seizures,
weak muscle tone (hypotonia), and
abnormalities in the cerebrum
Yes (high-grade glioma
[78])
IDH2 inhibitors such as
enasidenib [79]
JAK3 R651W,
V599G,
W709R
Severe combined
immunodeficiency
[80]
Lack the necessary immune cells to
fight bacteria, viruses, and fungi
None found Mutations cause loss of
function and hence JAK
inhibitors such as tofacitinib
[81] will not be effective
KRAS P34R Cardiofaciocutaneous
syndrome [54, 82]
Distinctive craniofacial appearance,
and cutaneous abnormalities
(including but not limited to xerosis,
hyperkeratosis, pigmented moles,
hemangiomas)
Yes (juvenile
myelomonocytic leukemia,
brain tumor, acute
lymphoblastic leukemia,
rhabdomyosarcoma, and
neuroblastoma [55])
MEK inhibitors [83] such as
trametinib [75]
MET F841V DFNB97 hearing loss
[84]
Non-syndromic sensorineural hearing
loss with prelingual onset
None found The mutation is damaging, so
MET inhibitors such as
cabozantinib [85] should not
be effective
NOTCH1 C1496Y,
D1989N
Adams-Oliver
syndrome [86]
Congenital aplasia cutis and
malformations of the limbs
None found Loss-of-function mutations so
Notch inhibitors such as
LY3039478 [87] will be
ineffective
NF1 R304X,
Y2264X,
R1825W,
R1809C,
N1229S,
D176E
Neurofibromatosis
type 1 [88]
Changes in skin coloring
(pigmentation) and the growth of
benign neoplasms along nerves in
the skin, brain, and other parts of the
body [89]
Yes (malignant peripheral
nerve sheath tumors, optic
gliomas, brain tumors,
breast cancer [90])
MEK inhibitors [91] such as
trametinib [75] or selumetinib
[92]
NF2 L46R,
L141P,
A211D,
K413E, Q324L,
and L535P
Neurofibromatosis
type 2 [93]
Growth of benign neoplasms in the
nervous system; vestibular
schwannomas or acoustic neuromas
None found mTOR inhibitors [94] such as
sirolimus [53]
RET P155L,
T278A,
T278P,
D300N,
S316I,
C620R
Hirschsprung disease
[95]
Absence of nerves in distal colon Yes (medullary thyroid
[96, 97])
Mutations generally cause loss
of function, so RET inhibitors
such as LOXO-292 [98] or
cabozantinib [83] would be in
effective; RET C620R may cause
both gain and loss of functions
STK11 40 different
somatic
STK11
mutations
Peutz-Jegher
syndrome
Gastrointestinal hamartomatous
polyps and hyperpigmentation of the
lips, buccal mucosa, digits
Yes (gastrointestinal tract,
pancreas, cervix, ovary, and
breast [100])
mTOR inhibitors such as
everolimus [101]
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with an increased risk of malignant transformation be-
cause of their underlying oncogenic driver. In such con-
ditions, an approach aimed at deploying anti-cancer
drugs to target molecular alterations in benign disease
might also be exploitable to prevent cancers.
Sporadic benign conditions associated with
alterations in “driver” cancer genes
With the advances in next-generation sequencing (NGS)
and the resulting identification of driver mutations for
various cancers, there has been growing interest in the
phenomenon in which well-known cancer-causing genes
are altered in benign conditions, some of which have ei-
ther no (or very limited) potential for malignant trans-
formation (Table 1): (i) FGFR3 activating mutations are
well documented to play a major role in the pathogen-
esis of bladder cancer [124–126], yet they are also found
in unrelated conditions such as seborrheic keratosis and
epidermal nevi [19–22]; (ii) mutations in the TP53
tumor suppressor gene, which are perhaps the most
common alterations in cancer [140], also characterize
the synovium of rheumatoid arthritis [37, 38]; (iii) KRAS
mutations are found in arteriovenous malformations [35,
36, 141] and in endometriosis [27] (though their func-
tional role is still unclear in these conditions); and (iv)
brain somatic mutations in Alzheimer’s disease, in which
about 27% of patients (14 of 52) have alterations in
genes of the PI3K-AKT, MAPK, and AMPK pathways,
are known to contribute to hyper-phosphorylation of tau
[47]. Importantly, some of the loci that are mutated in
each of these cases do not differ from the loci that are
mutated and implicated in cancer. The mechanism by
which such mutations cause these benign conditions but
fail to cause cancer is unclear, but we hypothesize that
aberrant tissue growth that is associated with FGFR3
mutations is dependent on the tissue- or cell-type con-
text of these mutations; when they are found in the epi-
dermis, benign seborrheic keratosis develops [19–22],
whereas when they appear in the bladder, cancer de-
velops [124–126]. A similar mechanism could be posited
for KRAS mutations and arteriovenous malformations.
In the case of TP53 mutations, which are clearly related
to the formation of multiple cancers [140], perhaps they
induce the inflammatory condition rheumatoid arth-
ritis, rather than cancer, in the synovium [37, 38].
Arthritis might ensue because TP53 mutations
Table 2 Examples of hereditary germline syndromes and of somatic mosaicism associated with examples of alterations in cancer-
driver genes, their relationship with cancer in affected patients, and targeted drugs that might be useful (Continued)
Gene Alteration Syndrome Descriptions Increased incidence of
cancer (if yes, most
common cancers)
Treatment potentially/
theoretically targeting the
alteration
[99]
TP53 Multiple
loss of
function
mutations
Li-Fraumeni [102–
105]
Greatly increases the risk of several
cancers
Yes (sarcoma, breast, brain,
adrenocortical [102])
Bevacizumab may target
angiogenesis associated with
TP53 mutations [39]
Somatic mosaicism
AKT1 E17K (gain
of function)
Proteus syndrome
[106]
Overgrowth of the bones, skin, and
other tissues
Yes (meningiomas, ovarian
cystadenomas, breast
cancer, parotid
monomorphic adenoma,
mesothelioma [107])
AKT inhibitors such as
ipatasertib [108]
GNAQ R183Q Sturge-Weber
syndrome [109]
Port-wine stains affecting the skin,
leptomeningeal vascular
malformations
None found Some MEK inhibitors may have
activity
PIK3CA E545K Hemimegalencephaly
[110]
Rare neurological condition in which
one-half of the brain, or one side of
the brain, is abnormally larger than
the other
None found PIK3CA inhibitors such as
alpelisib [24]
H1047R,
C420R,
Q542K
CLOVES syndrome
[111]
Tissue overgrowth and complex
vascular anomalies; CLOVES stands for
congenital lipomatous (fatty)
overgrowth, vascular malformations,
epidermal nevi and scoliosis/skeletal/
spinal anomalies
Yes (Wilms tumor [112]) PIK3CA inhibitors such as
alpelisib [26, 113]
H1047R
and H1047L
Fibroadipose
hyperplasia [114]
Patchy overgrowth of a limb or part/
region of the body
None found PIK3CA or mTOR inhibitors
[115] such as alpelisib [26] or
everolimus [101]
*A recent publication [64] shows that craniosynososis may be associated with increased incidence of hepatoblastoma, although the authors did not define which
syndromes were affected
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upregulate levels of the inflammatory cytokine
interleukin-6 (IL-6), a known pathogenic factor in
rheumatoid arthritis [142, 143].
An example that defies the tissue- or histology-context
hypothesis is BRAF V600E, a known oncogenic driver
that occurs in around 80% of benign nevi [3, 4]. These
nevi are extremely common and are estimated to have a
transformation-to-melanoma rate of less than 0.03% for
melanocytic nevi [144] and only about 4.8% for dysplas-
tic nevi [145]. Yet, in the setting of melanoma or other
tumors, there can be no doubt regarding the oncogenic
role of BRAF V600E mutations, based on preclinical
modeling [146] and also on the tumor regression that re-
sults from the use of antagonists such as BRAF and
MEK inhibitors [5, 75]. Explanations for the lack of
pathogenicity of BRAF V600E in benign nevi include,
but are not limited to the following: (i) RNA silencing, a
mechanism whereby deleterious DNA alterations are not
expressed at the RNA level [147]; or (ii) the possibility
that a “double hit” [148], a concomitant loss of an
inhibitor or the activity of a genomic co-factor [149], is
necessary in order to initiate carcinogenesis. Another
possible mechanism by which oncogenic mutants can
exist in normal tissue but not cause cancer is illustrated
by a study that showed that normal human esophagus
contains TP53-mutant progenitors. Yet, TP53-mutant
cells can be displaced from normal tissues through the
improvement of the competitive fitness of wild-type pro-
genitors by antioxidants [150].
Both normal aging and specific environmental expo-
sures can also be associated with somatic oncogenic mu-
tations. For instance, in natural aging of the esophagus
and in rapidly proliferating tissues such as those in the
testes, mutations in known oncogenes such as NOTCH1
[33], PIK3CA [28], TP53 [33], and KRAS [28] may ap-
pear. Indeed, in middle-aged and elderly persons, it was
found that cell clones containing cancer-associated
mutations covered much of the esophageal epithelium,
with NOTCH1 and TP53 mutations affecting 12–80%
and 2–37% of cells, respectively [33]. The progressive
Fig. 1 Examples of reverse clonal selection. Aberrant cancer drivers that are paradoxically more frequent in benign or premalignant counterparts
than they are in the malignant condition. BRAF mutations included V600E [3, 4, 8, 117–120] and HER2 overexpression [121–123]. FGFR3 mutations
included R248C, S249C, and G372C [124–126]. JAK2 mutations included V617F [127–129]. % given is the percentage of cases in which there are
alterations (e.g., 70–88% of melanocytic nevi have BRAF mutations)
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age-related expansion of clones that carry mutations in
driver genes in the esophagus can be accelerated sub-
stantially by smoking and by alcohol consumption.
Although the remodeling of the esophageal epithelium
by driver-mutated clones is an inevitable part of normal
aging, lifestyle risks may also affect cancer development
[151]. Somatic mutations also emerge in skin that is
exposed to ultraviolet light [152]. Indeed, aged, sun-
exposed skin is a patchwork of thousands of evolving
clones with over 25% of cells harboring cancer-causing
mutations while preserving epidermal functions.
Similarly, age-associated clonal hematopoiesis, which is
caused by acquired mutations in myeloid cancer-
associated genes such as DNMT3A or TET2, is highly
prevalent in the normal population. Its biological impact
on hematopoiesis, etiology, and oncogenic risk is poorly
delineated at this time [153–156]. Finally, probable
driver mutations have been reported in around 1% of
normal colorectal crypts in middle-aged adults, indicat-
ing that carcinomas are rare outcomes despite a perva-
sive process of neoplastic change in morphologically
normal colorectal tissue [157]. The degree to which the
size of the mutant clones influences risk of malignant
progression warrants further exploration [158].
A critical question as regards mutations that arise with
aging, or as a result of exposure to smoking or other
noxious environmental factors, relates to the mecha-
nisms that promote or prevent cancer development. Im-
mune surveillance may play an important role in
explaining the presence of oncogenic drivers in benign
conditions without progression to malignancy. It could
be postulated that natural immune mechanisms may
eradicate cells that present neo-antigens derived from
these mutations. Failure of this immune surveillance
might result in cancer. Indeed, findings in both mouse
models of cancer and humans with cancer offer compel-
ling evidence that immune cell types and effector path-
ways collectively function as potent tumor suppressor
mechanisms [159, 160]. Furthermore, it has been shown
that the ability of various individuals’ major histocom-
patibility complexes to present neo-antigens that are
produced by the mutanome shapes the mutational land-
scape in cancers and may predict each patient’s suscepti-
bility to specific tumors [161].
In summary, oncogenic drivers are found in a range of
benign conditions as well as in normal tissues, especially
with aging. Their limited transformation potential or
failure to induce cancers consistently [157] can be hy-
pothesized to be due to several reasons including, but
not limited to, tissue and cellular context, a need for
genomic driver co-factors or for co-loss of genomic sup-
pressors, the suppressive or competitive growth of pro-
genitors with normal molecular landscapes, the size of
the mutant clones, and immune surveillance.
Hereditary conditions that result from germline
cancer-related genes have a range of malignant
potential
Cancer-associated genes can be altered at the germline
level, and yet individuals with these genes may have a
wide spectrum of cancer risk, from no increased risk to
very high risk (Table 2). It is unclear as to why there is a
range of cancer susceptibility, but this range could be re-
lated to immune surveillance mechanisms [161]. As an
example, patients with “RASopathies” (a group of rare
genetic conditions such as cardiofaciocutaneous syn-
drome and Costello syndrome caused by mutations in
genes of the RAS-RAF-MAPK pathway) have an in-
creased risk of juvenile myelomonocytic leukemia, brain
tumors, acute lymphoblastic leukemia, rhabdomyosar-
coma, and neuroblastoma [55]. These patients do not,
however, have increased risk of classic BRAF-mutated
melanoma, although ~ 75% of the cardiofaciocutaneous
syndromes result from germline BRAF mutations [162],
and pigmented nevi are very distinct in this syndrome
and help to define it [163].
In other familial syndromes, such as Von Hippel-
Lindau, patients harbor a VHL mutation, which has been
best defined in clear cell renal cell carcinoma, and subse-
quently are at significant risk of developing renal cancers
[164]. Li-Fraumeni syndrome is another example of a
hereditary cancer syndrome in which TP53 mutations
predispose patients to cancers of the breast, brain, or ad-
renocortical organ, or to sarcomas [102]. Further, the
APC gene mutation is a well-defined and known cause
of familial adenomatous polyposis, and afflicted individ-
uals are at significant risk of developing colorectal car-
cinoma [49, 50].
On the other hand, there are hereditary conditions
caused by “oncogenic driver mutations” that have no
clear association with increased cancer risk (although
large-scale studies of these diseases are not fully devel-
oped and it is conceivable that, with time, some in-
creased cancer risk might be identified). Examples
include achondroplasia, hypochondroplasia, lacrimo-
auriculo-dento-digital syndrome, and thanatophoric dys-
plasiam, each of which is attributed to germline FGFR3
mutations that result in their varied phenotypes
(Table 2). Patients with neurofibromatosis type 2 also
seem to have no clear association with an increased can-
cer risk [93].
In summary, germline oncogenic mutations are associ-
ated with a variety of aberrant phenotypes and a wide
spectrum of increased cancer risk (ranging from negli-
gible to very high). The reasons for the variance in vul-
nerability to malignancies are unclear but could involve
the immune machinery [159–161, 165]. It is also pos-
sible that heterozygosity may, in some cases, play an an-
tagonistic role in tumor initiation and malignant
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transformation (even while accelerating the formation of
benign neoplasms), as shown for NF1 [166]. Patients
who carry some of these germline oncogenic alterations
need to be monitored, often throughout their lifespan,
for specific cancers on the basis of their diagnosis and
the known propensity to malignancy, with cancer risk
being determined by epidemiologic studies.
Somatic mosaic conditions that are associated
with oncogenic drivers but without clear
increased cancer risk
Somatic mosaicism is defined by the occurrence of two
genetically distinct populations of cells within an indi-
vidual, derived from a postzygotic mutation [167]. Un-
like inherited mutations, somatic mosaic mutations may
affect only a portion or a tissue of the body and are not
transmitted to offspring. The phenotypic consequences
of somatic mosaicism are dependent upon the biologic
impact of the mutation, as well as on the developmental
time at which the mutation occurs and the areas of the
body that are affected [168].
Several somatic mosaic conditions are associated with
gene abnormalities identical to those in cancer but result
in a phenotypic presentation other than cancer (Tables 2
and 3). Sturge-Weber syndrome is a neurocutaneous
vascular malformation syndrome, characterized by a fa-
cial port-wine birthmark, which is associated with chor-
oid “angioma” of the eye and malformed leptomeningeal
blood vessels, as well as with seizures, strokes, stroke-
like episodes, and neurologic deficits, beginning in
infancy [109]. It is caused by a somatic (not heritable)
mosaic mutation in GNAQ. This activating mutation in
GNAQ (R183Q) results in constitutive overactivation of
the Ras-Raf-MEK-ERK pathway and is identical to the
GNAQ alteration implicated in uveal melanoma [173,
174]. It has been hypothesized that the occurrence of
the GNAQ mutation at a different time in development
(in the fetal period or in infancy rather than in adult-
hood) accounts for its resulting in a vascular malforma-
tion rather than a cancer [175].
Fibroadipose hyperplasia is characterized by patchy
overgrowth of a limb or of a part or region of the body.
It is associated with PIK3CA H1047R mutations, which
are implicated in multiple cancers [114, 115, 171]; yet,
this condition is not known to associate with cancer,
although further longitudinal studies are necessary.
Hemimegalencephaly, a condition in which one side of
the brain is larger than the other, is also attributed to an
activating PIK3CA E545K that is indistinguishable from
the alteration observed in several types of malignant
neoplasms, but there is no clear cancer risk in hemime-
galencephaly [176, 177].
In summary, as for conditions that are associated with
germline mutations, conditions caused by somatic
mosaic mutations may be associated with aberrant tissue
growth and with a range of cancer risks (Table 2).
Cancer risk may relate to the actual mutation involved,
tissues affected and developmental period, and to other
poorly studied factors such as immune function. Because
these conditions are very rare, it is conceivable that
more in-depth investigations of them will reveal some
increased cancer risks, even in those conditions that are
currently not believed to carry such a risk. Epidemio-
logical surveys are needed in order to define cancer risk
in these disorders fully. However, such studies may be
challenging because of the rarity of the disorders. Finally,
for patients who have elevated cancer risk, lifetime mon-
itoring for the specific cancers that are most likely to
occur is needed.
The paradox of reverse clonal evolution and
selection
The classic theory of clonal evolution and selection
posits that driver alterations cause cancer progression
from benign to premalignant lesions and then to inva-
sive malignancy (Fig. 1). Indeed, cancers are believed to
evolve by a reiterative process of clonal expansion, gen-
etic diversification, and clonal selection within the adap-
tive backgrounds of tissue bionetworks [178]. Clonal
evolution involves the interplay of advantageous or
“driver” alterations that give a cancer cell a fundamental
growth advantage, genomic alterations that enhance the
rate of other DNA changes by creating genomic instabil-
ity (“mutator” genes), neutral or “passenger” (hitchhiker)
gene alterations that do not directly determine cancer
development, and modifications to the tumor habitat
that refashion the fitness effects of each of these
abnormalities [179–181]. The dynamics are complex,
with highly variable configurations of genetic diversity
and ensuing clonal architecture. Further, evolutionary
selection pressures that operate at a multicellular level—
and therefore can be distinct from the clonal events that
drive initiation and the benign-to-malignant transition—
govern late-stage tumor progression and metastases
[116, 182]. These issues are important because thera-
peutic interventions are aimed at driver alterations,
which must be distinguished from passenger mutations.
It has been previously assumed that hotspots, meaning
sites in the genome that are prone to mutations across
multiple tumors, are drivers of tumorigenesis; however,
it has been demonstrated more recently that many hot-
spot mutations represent passenger events, recurring at
sites that are simply more predisposed to mutation
[183]. Impacting driver mutations may decimate cancer
clones and their ecosystems, but may also provide potent
selective pressure for the emergence and/or expansion
of resistant molecular alterations [116].
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A canonical understanding of clonal evolution and se-
lection suggests that driver alterations should appear
more frequently as the continuum progresses from be-
nign to premalignant to malignant neoplasm. Tradition-
ally, it would be assumed that, for example, a BRAF
V600E mutation—identified as a known driver of melan-
oma on the basis that mutated BRAF proteins have ele-
vated kinase activity and are transforming in NIH3T3
cells [117]—would be found most abundantly in melano-
mas rather than in dysplastic or benign nevi. On the
contrary, however, the incidence of the BRAF V600E
mutation in benign nevi and premalignant conditions or
dysplastic nevi is more frequent (~ 70–88% and ~ 60%,
respectively) than in melanoma (~ 40–45%) (Fig. 1), des-
pite the fact that the conversion rate of benign nevi to
melanoma is negligible [144]. Another example that
Table 3 Examples of sporadic and hereditary conditions and of somatic mosaic non-malignant conditions that have been treated
successfully in animal models or in patients by targeting underlying “oncogenic” drivers using drugs, some of which were
developed for cancer
Condition Underlying
molecular
defect
Therapy Result of therapy Comments FDA-approved
drug: cancers
treated
Sporadic conditions
Rheumatoid
arthritis
TP53 mutations Tocilizumab,
which is an
anti-IL-6 re
ceptor
antibody
Decreased incidence of flares,
better disease control [169]
Efficacy in humans; TP53
mutations are known to
increase IL-6, which mediates
inflammation [142]
None
Desmoid tumors CTNNB1
mutations
COX-2
inhibitors and
sorafenib
Tumor regression [5, 145, 146] Efficacy in humans; COX-2
inhibitors and sorafenib can
abrogate the activation of
the WNT pathway by
CTNNB1 alterations
[13, 41, 42]
COX-2
inhibitors:
none
Sorafenib:
renal cell
carcinoma,
hepatocellular
carcinoma
Inflammatory
myofibroblastic
tumors
ALK
rearrangements
Crizotinib Sustained objective responses [30] Efficacy in humans; crizotinib
is a potent ALK inhibitor
Non-small cell
lung cancer
Schnitzler
syndrome
MYD88 L265P
mutation
Anakinra,
which is an IL-
1 antagonist
Complete remission of disease [170] Efficacy of anankinra in
humans
None
Neurofibromatosis
1
NF1 mutations MEK inhibitor
selumetinib
71% partial response rate for
inoperable plexiform neurofibromas
[92]
FDA granted breakthrough
status for selumetinib for
NF1 in 2019
None
Hereditary and somatic mosaic conditions
CLOVES syndrome Mosaic gain-of-
function PIK3CA
alterations
Alpelisib,
which is
PIK3CA
inhibitor
Improved disease-related symptoms
[113]
Efficacy in humans Hormone-
positive, HER2-
negative
breast cancer
Central
conducting
lymphatic
anomaly
Gain-of-
function ARAF
mutations
(MEK or mTOR
pathway)
Sirolimus
(mTOR
inhibitor) or
trametinib
(MEK
inhibitor)
Resolution of chylous output over the
course of a week with removal of
chest tube with sirolimus (n = 1) [53]
Dramatic clinical improvement, with
remodeling of the patient’s lymphatic
system and resolution of the lymphatic
edema, marked improvement in pulmonary
function tests, cessation of supplemental
oxygen requirements and near normalization
of daily activities with trametinib (n = 1) [51]
Efficacy in humans Sirolimus:
none
Trametinib:
melanoma
Fibroadipose
hyperplasia
PIK3CA
mutations
Sirolimus
(mTOR
inhibitor)
Stabilization or improvement in disease in
patients [115, 171]
Efficacy in humans None
Achondroplasia FGFR3
mutations
FGFR3
inhibitor in
mouse
models
Restored size of embryonic achrondroplastic
femurs in animals [172]
Animal model efficacy None
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contradicts the classic theory of clonal expansion is
HER2 overexpression, a clearly druggable driver of
breast malignancies, which is nonetheless identified
more commonly in ductal carcinoma in situ (~ 27–56%)
than in invasive mammary cancers (~ 11–20%) [121–
123]. Similarly, grade of bladder cancer is inversely re-
lated to the frequency of driver FGFR3 mutations. As
successive grades are diagnosed, the incidence of FGFR3
mutations decreases: non-invasive, grade 1 bladder can-
cer has the most frequent occurrence of FGFR3 muta-
tions (~ 61%), then non-invasive, grade 2 bladder cancer
(~ 58%), followed by non-invasive, grade 3 bladder can-
cer (~ 34%), lamina propria-invasive grade 3 (~ 17%),
and, last, high-grade tumors, which demonstrate FGFR3
mutations in only about 11% of cases [124–126]. This
paradoxical phenomenon is also seen in hematologic
malignancies. JAK2 mutations are found in the majority
of myeloproliferative disorders (65–97%), but rarely in
acute myeloid leukemias (2–5%) [127–129, 184, 185]. In
each of the examples mentioned above, there can be lit-
tle question regarding the driver role of these alterations
because of the efficacy of drugs developed against them
in achieving tumor regression.
The mechanism that underlies the paradoxical
decrease in the frequency of driver alterations with
malignant progression is unknown. However, the
phenomenon is especially pertinent to therapeutic drug
development because it is critical that one does not as-
sume that a mutation or other alteration is a passenger
just because it is more frequently found in the benign
counterpart of an invasive cancer. Had such an assump-
tion been made, BRAF inhibitors would not have been
developed for melanoma. Another question is how onco-
genic drivers that are less frequent in malignant disease
than in benign disease act to impart the oncogenic
phenotype in the malignancy, but not in the benign le-
sions. Perhaps the driver alteration acts in an oncogenic
capacity only when a required co-factor or co-alteration
is in place, or perhaps the suppression of an endogenous
inhibitor is required in order for the malignancy to
emerge [186]. Preclinical and ex vivo studies examining
the functional effects of mutations in various tissue con-
texts and with different co-alterations can be performed
with a variety of techniques, including patient-derived
cell cultures that serve as avatars [187]. These studies
may provide a biologic understanding of the role of
these mutations in determining the aggressiveness of a
tumor, and whether or not malignant transformation
takes place.
Therapeutic implications of oncogenic drivers in
non-malignant conditions
In many instances, there are approved drugs that specif-
ically target a gene mutation product and are readily
available for use in the setting of a malignancy. Using
the same gene-targeting paradigm and shifting it to-
wards sporadic benign diseases, hereditary conditions or
somatic mosaic syndromes that carry the cognate driver
genomic aberration (regardless of their malignant poten-
tial) could offer innovative treatments for these condi-
tions, perhaps reversing their phenotype. Factors that
would need to be considered would be the potency of
the agent against the genomic target and its potential
toxicity. For disorders that have potential for malignant
transformation, it is conceivable that the use of such tar-
geted agents might also attenuate the risk of developing
cancer.
Repurposing cancer drugs for sporadic conditions
Several examples now exist to demonstrate how the tar-
geting of genomic drivers in benign illnesses can allevi-
ate disease, and to show that drugs that were developed
for illnesses on the neoplastic spectrum can be used
(Table 3). For instance, tocilizumab is an anti-IL-6-re-
ceptor monoclonal antibody approved for use in
rheumatoid arthritis and also developed for the treat-
ment of Castleman disease, a lymphoma-like condition
[169]. TP53 mutations, which are known to occur in the
synovium in rheumatoid arthritis [37, 38], upregulate IL-
6 levels [142, 143], perhaps mediating the inflammation
of arthritis and explaining the efficacy of tocilizumab in
this condition. Desmoid tumors provide another ex-
ample; these neoplasms are an aggressive fibromatosis
that have similarities to fibrosarcoma but are considered
benign because they do not metastasize. They are char-
acterized by CTNNB1 mutations [41], which are known
to activate the WNT pathway [13]. They can be treated
with COX-2 inhibitors such as celecoxib (approved for
familial adenomatosis polyposis, which predisposes
carriers to colorectal cancer) and/or with sorafenib
(approved for several types of cancer), both of which
suppress the WNT pathway [14, 42, 43].
Another example is inflammatory myofibroblastic
tumor, which is an uncommon, usually benign neoplasm
composed of myofibroblastic spindle cells with an
inflammatory infiltrate. Approximately half of inflamma-
tory myofibroblastic tumors carry rearrangements of the
anaplastic lymphoma kinase gene locus (ALK) on
chromosome 2p23, causing aberrant ALK expression.
After the initial report of a striking response to treat-
ment with the ALK inhibitor crizotinib (approved for
lung cancers with ALK rearrangements) in a patient
suffering from an ALK-rearranged inflammatory myofi-
broblastic tumor [30], a larger study showed that six of
12 ALK-positive patients (50%) achieved an objective re-
sponse with crizotinib [188].
Finally, in Schnitzler syndrome, a rare auto-
inflammatory disease that often presents with urticarial
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rash, fever, lymphadenopathy, musculoskeletal pain, and
thrombosis and that is attributed to cytokine dysregula-
tion involving IL-1β and the inflammasome pathway,
there is evidence that blocking IL-1 can lead to signifi-
cant disease control [170]. We previously described a pa-
tient with Schnitzler syndrome and a MYD88 mutation;
the latter is classically discerned in Waldenström macro-
globulinemia. Treatment with anakinra, an IL-1 receptor
antagonist (IL-1RA), resulted in a durable response
[170]. This beneficial effect may be due to the fact that
MYD88 plays an important role in IL-1 signaling, medi-
ating the association between IL-1R- and the IL-1R-
associated kinase (IRAK) [189].
Theoretical examples also exist. For instance, drugs
that target PIK3CA or MEK signals, such as alpelisib or
trametinib, respectively, may theoretically offer new op-
tions for women suffering with endometriosis, which
harbors mutations in PIK3CA or KRAS [27]. In sporadic
brain arteriovenous malformations (AVMs) that are
caused by KRAS mutations, using agents that inhibit the
MAP-ERK pathway could also offer potential therapy for
patients, at least in theory [35]. These AVMs have po-
tential to rupture and cause significant morbidity in
these patients.
Taken together, these observations suggest that drugs
that impact driver molecular alterations or their down-
stream effectors can be repurposed to treat a variety of
benign, sporadic illnesses, and that such new uses merit
investigation in clinical trials that select drugs for non-
malignant conditions on the basis of their somatic alter-
ations. Nevertheless, several caveats would need to be
considered. These include the possibility that the drug
action might depend on tissue context and that potential
side effects might attenuate the ability to administer the
drug to patients who are afflicted with non-malignant
conditions.
Repurposing cancer drugs for somatic mosaic and
germline conditions
Gene-product targeted drugs may also be beneficial in
hereditary or somatic mosaic conditions (Table 3). A
dramatic example is provided by CLOVES syndrome
(congenital lipomatous overgrowth, vascular malforma-
tions, epidermal nevi, scoliosis/skeletal, and spinal syn-
drome), which is a disorder that results from somatic,
mosaic gain-of-function mutations of the PIK3CA gene
and that belongs to the spectrum of PIK3CA-related
overgrowth syndromes. Previously, this ultra-rare condi-
tion had no specific treatment and a poor survival rate.
Use of the PIK3CA inhibitor alpelisib improved disease-
related symptoms in all of the 19 patients that received
the drug [113]. Intractable vascular tumors became
smaller, congestive heart failure was improved, hemihy-
pertrophy was reduced, and scoliosis was attenuated.
The treatment was not associated with significant
toxicity at doses of alpelisib of 250 mg by mouth per day
in adults taken for a period of up to 18months (the ap-
proved dose for breast cancer starts at 300 mg per day);
children received 50mg per day with excellent tolerance.
A second illustration of the repurposing of medica-
tions has been described in patients with central con-
ducting lymphatic anomaly, in which aberrations can
occur along the MAPK or mTOR pathways [52]. The
use of sirolimus (a mTOR inhibitor) [53] or trametinib
(a MEK inhibitor) [51] provided significant benefit and
attenuation of disease in treated patients. For example, a
patient given sirolimus, who required a chest tube for
the abundant output of chylous effusion, attained a
complete resolution of chylous output and no longer re-
quired the chest tube [53]. In the patient treated with
trametinib, there was resolution of the lymphatic edema,
improvement on pulmonary function tests so that the
patient no longer required supplemental oxygen, and
significant improvement in functional status [51]. In
other words, the phenotype of these genetic disorders
was reversed by precise targeting of the molecular ab-
normality using a drug developed for cancer.
Another example pertinent to the repurposing of drugs
for benign illness pertains to NF1, a gene whose aberration
activates the MEK pathway. Neurofibromatosis-1 is a her-
editary condition caused by germline NF1 mutations; it
manifests mainly with non-malignant neurofibromas,
which nonetheless cause functional disabilities. Recently,
the MEK inhibitor selumetinib was given Breakthrough
Status by the FDA for this condition because of a ~ 70%
response rate in children with neurofibromatosis-1 and in-
operable plexiform neurofibromas [92]. Of interest, NF1
mutations may also be found in melanoma, but some
studies suggest that targeting them with MEK inhibitors
would be ineffective (though there may be exceptions)
[190]. Melanomas with NF1 mutations may not respond
to MEK inhibitors (although neurofibromatosis is respon-
sive) because melanomas tend to have important co-
alterations, whereas neurofibromatosis is driven only by
NF1 alterations [191, 192].
Finally, targeting activating FGFR3 mutations in
achondroplasia with FGFR inhibitors is another example
worth noting, although the data here are from animal
models only [23]. In a mouse model with FGFR3-mu-
tated skeletal cells, use of an FGFR3 inhibitor led to res-
toration in the size of achrondroplastic femurs [172].
FGFR mutations cause multiple skeletal disorders and
also play a role in certain cancers. Targeting these muta-
tions could potentially abrogate the skeletal anomalies
seen in these hereditary conditions. However, if the lack
of increased cancer risk in these patients is due to a
compensatory factor that develops in the presence of
germline activated FGFR3, and if this compensatory
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factor is attenuated in the presence of FGFR inhibitors
given during early life stages, it would be important to
take into consideration the theoretical possibility of a
later cancer risk if these FGFR3 inhibitors were discon-
tinued [193].
Confounding the holy grail—early detection of
cancer with blood tests
In recent years, liquid biopsy to detect cfDNA or
circulating tumor DNA (ctDNA) has emerged as an
attractive non-invasive methodology to discern cancer-
specific genomic aberrations in plasma. Numerous
studies have reported the utility of ctDNA in advanced
cancer [194–197]. In particular, ctDNA assays can cap-
ture a more global portrait of tumor heterogeneity than
that provided by tissue DNA (which reflects the small
piece of tissue that is biopsied rather than DNA shed
from both primary and multiple metastatic sites [198]);
therefore, ctDNA can be exploited to monitor tumor re-
sponse and resistance.
Recently, ctDNA analysis has also been proposed as a
promising future tool for the identification of early neo-
plasms as part of cancer screening. As the average
amount of mutated DNA in plasma is very low (about
0.4% even in metastatic malignancies), exceedingly sensi-
tive technologies must be developed; further, in cancer
patients with low tumor burden, ctDNA is difficult to
detect [130, 199]. Hence, in patients without known tu-
mors who are being screened, the levels of ctDNA may
be very, very low. Yet, increased sensitivity of ctDNA
tests is a two-edged sword. It is plausible that with
overly sensitive tests, molecular alterations from benign
lesions would be picked up in cfDNA. Being able to dif-
ferentiate between these sources of ctDNA and to deter-
mine thresholds that correspond to levels of concern for
screening tools are areas of continuing development
[200]. It is also possible that serial tests may need to be
conducted and that increasing ctDNA levels with time
might be the trigger for further work up for cancer. In
addition, as cancers are heterogeneous at the molecular
level, any screening blood test would need to assay mul-
tiple gene targets in order to increase the chances of
finding a cancer.
Of significant interest, non-invasive prenatal testing,
which uses cfDNA as an analyte to detect copy-number
alterations in the fetal genome (by testing maternal
blood), can detect early cancers in pregnant women. In
one study, an abnormal genomic profile not consistent
with fetal abnormalities was identified in about 10 out of
100,000 cases; a significant subset of these observations
(18 of 43; 41.9%) was attributed to mostly unsuspected
maternal malignant neoplasms [201]. These findings
substantiate the claim that sensitive cfDNA screening
may be exploitable as a cancer biomarker for the early
detection of malignant disease.
In addition to cfDNA or ctDNA, other components of
tumors that are shed into the circulation may be import-
ant for early detection: circulating tumor cells or extra-
cellular vesicles. Indeed, these tumor components have
been informative for early recognition of relapse, albeit
of advanced tumors [202].
For the identification of early cancer, strategies for
analysis are in principle relatively similar to those for ad-
vanced disease. However, beyond the sensitivity issues
discussed above (i.e., very early-stage (asymptomatic) tu-
mors may not release enough ctDNA to be detectable in
a typical blood draw), the challenges with these tech-
niques are considerable. For instance, white blood cells
are a major source of cfDNA in blood, and it is crucial
to distinguish acquired mutations in leukocytes (benign
clonal hematopoiesis that increases with age [203]) from
incipient invasive cancer. Further, “oncogenic” mutations
can be found in healthy individuals, including in their
cfDNA, and can be indistinguishable from those associ-
ated with cancer [130]. Therefore, caution needs to be
applied when interpreting results from mutation-based
early detection tools, as both false negatives (resulting
from lack of sensitivity) and false positives (resulting
from the detection of shed DNA from benign lesions
that harbor oncogenic mutations) could confound the
interpretation of these tests. Other methods being ex-
plored to screen for cancers using blood-based methods
include the use of autoantibodies [204–208] and tumor-
associated antigens [209]. As regards technologies that
use circulating tumor cells or extracellular vesicles, in
addition to the low volume of the aberrations in the
blood, theoretically confounding phenomena must be
addressed. These might include the rate of clearance in
patients with renal or hepatic impairments, stability in
the bloodstream, diurnal or other biologic influences on
time of collection, the effects of smoking, pregnancy,
and other inflammatory conditions, and clonal expan-
sions of non-tumors.
Other technologies, including gene and protein ex-
pression signatures [210–214], have also been developed
to help to decipher the code that differentiates benign
and cancerous molecular anomalies. Intriguingly, there
are models that predict (with up to 90% accuracy) the
pattern of epigenetic changes found on circulating DNA
in the bloodstream that imply malignancy versus those
that do not [215]. Indeed, there is evidence that the me-
thyl clusters that occur on the cancer DNA not only
help to identify cancer DNA, but are major contributors
to carcinogenesis [215].
In summary, myriad blood-based assays are being de-
veloped for early detection of cancer. They include tests
of ctDNA mutations or methylation patterns as well as
Adashek et al. Genome Medicine           (2020) 12:16 Page 13 of 19
interrogation of exosomes or circulating tumor cells.
Validating these biomarkers will probably require serial
follow-up to discern an increasing level of abnormality
and will also need threshold trigger values for imaging
patients in order to confirm the presence of cancer.
Perspective and future directions
The rapid expansion of the use of NGS in cancer clinical
care and research has resulted in significant improve-
ment in outlook for a subset of malignancies [216–218].
Indeed, genomic markers can drive new clinical trials of
both gene- and immune-targeted agents [219–225].
Relatively new, however, is the emergence of data show-
ing that non-cancerous illnesses also have genomic
markers, and intriguingly, that some of these molecular
alterations are indistinguishable from those considered
oncogenic drivers for certain malignancies. Further
large-scale studies across benign conditions may provide
insight into crucial, subtle differences in the molecular
landscape that enable the same “driver” to navigate to-
wards two different “destinations”—that is, benign versus
malignant disease. Identifying potential co-alterations
may be key; alternatively, it may be that tissue of origin
or histologic context is critical or that immune function
shapes the outcome.
A wide variety of sporadic, mosaic, and hereditary con-
ditions can be characterized by “oncogenic” aberrations,
including conditions that have negligible malignant po-
tential (Tables 1, 2, and 3). Furthermore, there are now
several examples of the paradox of decreasing frequency
of the “oncogenic driver” as the condition progresses
from benign to premalignant to malignant (Fig. 1). Im-
portantly, recent RNA sequence analysis also identified
the somatic clonal expansion of mutations associated
with cancer across normal tissues, most commonly in
the lung, skin, and esophagus; the number of mutations
correlated with age and with tissue proliferation rate
[28]. The presence of these molecular abnormalities in
benign conditions may confound efforts to detect cancer
event cascades early through the use of blood tests. Ser-
ial blood tests may need to be done, with increasing
levels of the biomarker being indicative of a cancer
concern.
Of significant future interest is the potential to repur-
pose drugs used in cancer for non-malignant illnesses
that harbor actionable genomic alterations and/or to
prevent the development of cancer in conditions and
syndromes where there is a predisposition to malig-
nancy. The use of open-label basket clinical trials, in
which patients are matched with drugs on the basis of a
genomic aberration (regardless of histology), has been
effective in a variety of cancer settings [16, 226–229];
similar approaches could conceivably be taken in benign
conditions, for which trials that are disease agnostic
could be developed and drug choice would be dictated
by the genomic aberration. Alternatively, individual
sequencing studies of somatic or germline tissue may
define the treatment prosecution strategy on an N-of-
one basis in selected non-malignant diseases, as it is
beginning to do in malignancy [223]. Regardless, patients
would require close follow-up to determine whether
their cancer risk was modified by the use of matched
targeted agents, and functional studies on tissues might
help to identify those conditions that are most likely to
respond to cognate compounds. Finally, moving forward
in this field will require multidisciplinary collaborative
teams with expertise in the benign conditions, their ma-
lignant counterparts, and targeted drugs and genomics,
as well as translational scientists to bridge the emerging
preclinical and clinical data.
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